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Amélioration de la distribution de chimiothérapie par photothérapie dynamique 
intracavitaire pour la prise en charge des épanchements pleuraux malins 
Xingyu Wang, Dr Hans-Beat Ris, Dr JY Perentes 
 
Les épanchements pleuraux malins sont une pathologie difficile à gérer tant pour le patient en 
raison de la symptomatologie de dyspnée qu’ils entrainent que pour les soignants en raison de 
l’absence de thérapies satisfaisantes. La prise en charge de cette pathologie consiste, en 
général, en la combinaison d’une chimiothérapie palliative à une pleurodèse chirurgicale. 
Une des nombreuses raisons de la non-réponse tumorale à la chimiothérapie standard peut 
être expliquée par la vascularisation anormale des tumeurs. Ces dernières sont en effet 
dépendantes de la néo-angiogénése qui cause la création de réseaux vasculaires hautement 
perméables. Ceci résulte en une pression interstitielle intra-tumorale et des forces de 
convection fortement diminuées limitant le transport de molécules entre le milieu intra- et 
extracellulaire. 
Dans le passé, nous avons pu démontrer que le prétraitement du lit vasculaire tumoral par 
photothérapie dynamique à faible dose (L-PDT) pouvait moduler la vascularisation tumorale de 
façon à faire baisser la pression interstitielle tout en maintenant un flux de perfusion constant. 
Ceci résultait en une augmentation significative de la quantité et de l’homogénéité de la 
distribution de chimiothérapie dans des tumeurs solides qui prédit une meilleure réponse 
tumorale 
Dans ce travail de thèse, nous avons, dans un premier temps, confirmé et affiné les résultats 
préliminaires de modulation vasculaire tumorale par L-PDT. En combinant des modèles de 
carcinose pleurale à la microscopie intravitale, nous avons pu définir les conditions optimales de 
« fluence » et « fluence rate »  de la L-PDT afin d’obtenir la meilleure réponse vasculaire et le 
meilleur transport subséquent de chimiothérapie intratumorale. Nous avons ensuite confirmé 
qu’une meilleure distribution de chimiothérapie résultait en une meilleure réponse tumorale et 
avons validé ce concept dans 3 modèles tumoraux couvrant les épanchements carcinomateux 
les plus fréquents chez l’humain. Finalement, nous avons testé la faisabilité de l’approche de L-
PDT intracavitaire par thoracoscopie avec monitoring de fluence au cours du temps et effectué 
une étude toxicologique dans un modèle préclinique. Ces travaux ainsi que les précédents ont 
permis de finaliser une étude clinique de phase I qui validera la faisabilité d’une approche de L-
PDT intracavitaire combinée à une chimiothérapie liposomale dans la prise en charge des 
épanchements pleuraux malins chez l’homme. Cette étude va débuter en janvier 2016 et sera 
menée par le service de Chirurgie Thoracique du CHUV.   
Sur la base des éléments pré-cliniques de ce travail de thèse, la L-PDT intracavitaire permet 
une modulation du réseau vasculaire tumoral qui est favorable à la distribution subséquente de 
chimiothérapie. Ceci semble prédire une meilleure réponse tumorale chez l’homme par rapport 
à l’administration standard d’une chimiothérapie classique et un meilleur potentiel de contrôle 
tumoral et des symptomes. 
Lasers in Surgery and Medicine 47:323–330 (2015)
Fluence Plays a Critical Role on the Subsequent
Distribution of Chemotherapy and Tumor Growth Delay in
Murine Mesothelioma Xenografts Pre-Treated by
Photodynamic Therapy
Yabo Wang, MD, PhD,1# Xingyu Wang, MD,1# Marie-Aude Le Bitoux,2 Georges Wagnieres,3
Hubert Vandenbergh,3 Michel Gonzalez,1 Hans-Beat Ris,1 Jean Y Perentes,1# and Thorsten Krueger1#
1Department of Thoracic and Vascular Surgery, Centre Hospitalier Universitaire Vaudois,
Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland
2Department of Pathology, Centre Hospitalier Universitaire Vaudois, Ecole Polytechnique Federale de Lausanne,
Lausanne, Switzerland
3Department of Chemistry, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland
Background: The pre-conditioning of tumor vessels by
low-dose photodynamic therapy (L-PDT) was shown to
enhance the distribution of chemotherapy in different
tumor types. However, how light dose affects drug
distribution and tumor response is unknown. Here we
determined the effect of L-PDT fluence on vascular
transport in human mesothelioma xenografts. The best
L-PDT conditions regarding drug transport were then
combined with Lipoplatin
1
to determine tumor response.
Methods: Nude mice bearing dorsal skinfold chambers
were implanted with H-Meso1 cells. Tumors were treated
by Visudyne
1
-mediated photodynamic therapy with
100mW/cm2 fluence rate and a variable fluence (5, 10,
30, and 50 J/cm2). FITC-Dextran (FITC-D) distribution
was assessed in real time in tumor and normal tissues.
Tumor response was then determined with best L-PDT
conditions combined to Lipoplatin
1
and compared to
controls in luciferase expressing H-Meso1 tumors by
size and whole body bioluminescence assessment
(n¼7/group).
Results: Tumor uptake of FITC-D following L-PDT was
significantly enhanced by 10-fold in the 10J/cm2 but not in
the 5, 30, and 50 J/cm2 groups compared to controls.
Normal surrounding tissue uptake of FITC-D following L-
PDT was significantly enhanced in the 30 J/cm2 and 50J/
cm2 groups compared to controls. Altogether, the FITC-D
tumor to normal tissue ratio was significantly higher in the
10 J/cm2 group compared others. Tumor growth was
significantly delayed in animals treated by 10 J/cm2-L-
PDT combined to Lipoplatin
1
compared to controls.
Conclusions: Fluence of L-PDT is critical for the optimal
distribution and effect of subsequently administered
chemotherapy. These findings have an importance for
the clinical translation of the vascular L-PDT concept in
the clinics.Lasers Surg. Med. 47:323–330, 2015.
 2015 Wiley Periodicals, Inc.
Key words: photodynamic therapy; drug/light condi-
tions; tumor response; mesothelioma lipoplatin1
INTRODUCTION
Photodynamic therapy (PDT) consists in the adminis-
tration of a photosensitizer which, after activation by non-
thermal light produces a variety of biological changes in
normal and tumor tissues [1]. In cancer, PDT was initially
designed to destroy tumor cells [1]. More recently, PDT
was also shown to induce a variety of vascular changes
ranging from a transient vasospasm, drug convection
enhancement in tumor neovessels to a complete tumor
vascular shutdown [2–7]. The vascular effect of PDT
depends on the photosensitizer type and dose, the drug/
light interval, the optical fluence rate, total fluence and the
tissue properties (i.e. oxygen supply and levels) [8]. The
complex relationship between these parameters for vascu-
lar modulation and drug distribution enhancement has
beenwidely studied in normal tissues but is notwell known
in tumors [8–10]. In addition, the effect of fluence on the
tumor and normal tissue vascular transport enhancement
is currently a matter of debate [5].
We and others have shown that low-dose vascular
photodynamic therapy (L-PDT) could enhance the
extravasation of macromolecular compounds into tumors
in a variety of tumor types in different rodent models
[2,3,5,11–13]. The enhanced drug penetration in
tumors was observed with different modes of chemother-
apy administration (intravenous and isolated lung
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perfusion) and with different types of chemotherapeutics
[2,3,5,11,12].
Macromolecular therapeutics (>100 nm in diameter)
are known to depend on vascular convection for their
extravasation between the intra- and extra-vascular
spaces [14]. The latter is depicted by Starling’s equation
which includes two main parameters: tumor hydrostat-
ic and oncotic pressures. A hallmark of malignant
cancer is the high vascular permeability of neovessels
associated to increased interstitial fluid pressure (IFP)
which hinders convection and drug delivery [15–17]. We
have recently shown that L-PDT could cause a transient
drop in tumor but not normal tissue IFP while keeping
tumor blood flow constant and cause enhanced drug
convection in a somewhat similar phenomenon to
vascular normalization [4].
While it was shown that PDT administered with a high
fluence could cause drug convection enhancement in
normal tissue, the optimal fluence conditions for specific
tumor drug delivery improvement without affecting
normal tissue are currently unknown [4,5,9,10]. Also,
although drug distribution enhancement was demonstrat-
ed by L-PDT pre-treatment of tumors, it was never
demonstrated that this phenomenon corresponded to a
better drug efficiency on tumors.
Here, we assessed, by intravital microscopy, the changes
induced in tumor and normal tissue vasculature by L-PDT
administeredwith different fluences in amodel ofH-Meso1
xenograft grown in dorsal skinfold chambers. Based on
these results, we defined optimal L-PDT conditions and
combined this therapy with the administration of a single
dose of liposomal cisplatin (Lipoplatin
1
). Using H-Meso1
tumors transfected with a luciferase construct, we deter-
mined the changes in tumor cell viability and size in
animals treated with combined therapy (L-PDTþLip-
oplatin
1
) compared to controls (L-PDT alone, Lipoplatin
1
alone and controls) over a period of 28 days.
MATERIAL AND METHODS
Animal Model
Dorsal skinfold chamber. A human mesothelioma
tumor cell line (H-Meso1, Mason Worcester, MA, USA)
was implanted for donor tumor generation by injecting a
0.1ml cell suspension containing 2 107 tumor cells
behind the left scapula of nude mice (Charles River,
France). Tumors were grown up to 8mm in diameter. The
donor animals were then sacrificed and the tumors were
cut into chunks that were used for dorsal skinfold
chamber implantation. A custom built dorsal skinfold
chamber was implanted on the back of nudemice (Charles
River, France). This windowwas a custom design that has
the advantage to only weight 2 g and allow full tumor and
surrounding tissue observation thanks to the big size
coverslip. The model builds on a previously described one
from our laboratory [10]. Tumor chunks were prepared by
removing the capsule and the necrotic portions of the
donor tumor and by cutting the remaining tumor in
22 2mm cubes which were placed in a Petri dish and
immersed with cold PBS. The pieces were then placed into
the center of the dorsal skinfold chambers. The vasculari-
zation of the implanted tumor chunks was checked daily
and the experiments began when a stable perfused
vasculature was visible using transillumination micros-
copy (in general after 14 days). Tumor size at that time
was of approximately 4 4mm
Subcutaneous implantation of H-Meso1-Luc. To
evaluate the effect of combined L-PDT therapy at the
optimal fluence in combination with chemotherapy on
tumor growth, we used a heterotopic model of mesothelio-
ma transfected with luciferase (H-Meso1-Luc). Animals
were implanted with H-Meso1-Luc cells by injecting a
0.1ml cell suspension containing 2107 tumor cells
behind the left scapula. The intra-peritoneal injection of
luciferin is degraded by the luciferase and creates light
that can be measured by a bioluminescence assay (see
methods on whole body imaging). When tumors reached
30mm3, animals were randomly assigned to either control,
L-PDT alone, LipoplatinTM alone or L-PDT combined to
LipoplatinTM. Luciferin was injected at 75mg/kg. After
10minutes and for 30minutes, whole body biolumines-
cence was performed. All animals were kept in a sterile
environment and the experiments were conducted in
accordance with the National law and Institutional
guidelines for animal care and use.
Photodynamic Therapy
Animals included in the study underwent, according to
treatment groups, low-dose photodynamic therapy. For
this, Visudyne
1
, the photosensitizer, was administered
intravenously at a concentration of 400ug/kg. After a drug/
light interval of 10minutes, light was administered at a
fluence rate of 100mW/cm2 for a total fluence of 5, 10, 30
and 50J/cm2. This was performed using a 690nm laser
coupled to a 600um fiber containing a frontal light
distributor with a lens (Medlight, Ecublens, Switzerland).
Laser power and light dose were calculated based on the
geometry of the light path in order to irradiate the entire
window or tumor (tumorþnormal tissue) with a total light
dose of 5–10–30 and 50J/cm2. These doses were chosen
based on previously published experiments.
Intravital Microscopy
To evaluate the role of L-PDTfluence variation (5, 10, 30,
and 50 J/cm2) on the vascular transport of tumor/normal
tissues (FITC-Dextran 2MDa distribution, FITC-D) we
used nude mice bearing dorsal skinfold chambers and
implanted with H-Meso1 tumors. Tumors were treated
with L-PDT and had FITC-D injection after 60minutes.
The distribution of FITC-D was assessed over a period of
45minutes by epifluorescence microscopy. For this, a Carl
Zeiss Axiotech Vario 100 microscope was used for in vivo
observation of the dorsal skinfold chamber. For that
purpose, the mouse was placed in a lateral decubitus
position inside a plexiglas tube that was positioned under
themicroscope. The chamber on the back of the mouse was
fixed horizontally such that its position under the
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microscope allowed trans-illumination and at the same
time epi-illumination for fluorescencemicroscopy. Animals
were anesthetized by ketamine (80mg/kg) and xylazine
(10mg/kg). Achroplan Carl Zeiss 4x/0.10 Plan Neofluar
objectives were used for a large field of view (33mm).
Fluorescence excitationwas performed via a filtered 100W
HBO103 light source (OSRAM GmbH, Augsburg,
Germany), powered through a variable Carl Zeiss FluoArc
device. A Uniblitz shutter VS25 with its controller VMM-
D1 (Vincent Associates, Rochester, NY, USA) was used to
cut off the light from the HBO lamp. Images and video
sequenceswere recordedwith an on chip amplified electron
multiplier consisting of a back illuminated thinned Peltier
cooled CCD camera (EM-CCD C9100–12,400 to 1000nm,
Hamamatsu Photonics, Solothurn, Switzerland) allowing
for an up to 2000x amplified signal gain. This set-up
allowed the excitation light to be lowered, so as to prevent
both PDT and photobleaching from the analysis light.
Images and sequences were recorded through the Hama-
matsu camera controller with the Hamamatsu HiPic
version 7.0 software, producing 16 bit grey level images
with a size of 512512 pixels. AMultiscan Rate Converter
MSC-12A-HPK (Stack Ltd, Saitama, Japan) was added
between the EM-CCD and the controller providing digital
and video signals in parallel.
Quantification of FITC Dextran Leakage in Tumor
and Normal Tissues
The extravasations of FITC-D was determined by
epifluorescence microscopy, using excitation light from a
Hg-arc lamp filtered at 470 20nm by a Carl Zeiss “cube
filter set 09” (Exc. BP 450–490, DMFT510, Em. LP515)
with the 4x objective. The daily stability of theHg-arc lamp
was tested using a rubis 8Sp3 disc (diameter 12mm,
thickness 1mm, Hans Stettler, Lyss, Switzerland) as
previously described [9]. FITC-D fluorescence was
recorded in regions of entire dorsal skinfold chamber
consisting of tumor and normal tissue with different
treatment schemes. The intensity values of FITC-D were
recorded before, and every 10minutes following intrave-
nous injection. All intensity values for each observed
regionwere normalized to their initial value for analysis by
using a public domain ImageJ (version 1.37) software
(Rasband, W.S., ImageJ, US National Institute of Health,
Bethesda, Maryland, USA). This measurement was
performed in the tumor and in the normal surrounding
tissue. Quantification was performed in 5 animals per
group and analyzed as described in the statistical analysis
section.
Cell Culture and Luciferase Transfection
The human mesothelioma cell line H-Meso-1 was
transfected using a luciferase lentiviral construct
(pGL3). The latter was a kind gift from the Naldini Lab.
The resulting plasmid was sequenced to verify the
presence and integrity of the inserted luciferase cDNA.
Parental human mesothelioma cells (H-Meso1) were
cultured in DMEM supplemented with 10% FBS in a
humidified 5% CO2 incubator at 37 8C. Bulk cells trans-
duced with luciferase were obtained after two rounds of
lentiviral infection for 8hours and selected for puromycine
selection. The efficiency of luciferase expression was then
assessed in vitro by adding luciferin in the culture medium
at 150ug/ml and checking for light emission with the
bioluminescence assay.
In Vivo Bioluminescence Imaging
Tumor sizes were evaluated via in vivo bioluminescence
using the IVIS Imaging 200 series system (Xenogen
Caliper Life Sciences, Hopkinton Massachusetts, USA).
For this, animals were injected with luciferin intraperito-
neally (75mg/kg). After 10minutes, bioluminescence sig-
nals were captured sequentially over 30min. Maximal
photon flux images were acquired in the region of the
interest using Living Image Software (Xenogen) to gener-
ate the tumor growth curve. Data were expressed as
photon emission density (photons/s/cm2).
Tumor Size Assessment
Tumors were measured on daily basis using a caliper.
The volume of each tumor was calculated by length times
width to the power of 2 and divided by 2.
Statistical Analysis
A paired student’s two-tailed t-test was used to calculate
statistical differences of fluorescence ratios between the 5
and 50minutes time-points in the same groups. To analyze
the variables “fluorescence ratio” at a 50minutes time-point
in all groups, we applied an ANOVA test with Tukey’s HDS
post hoc test for multiple comparisons. Bioluminescence
data for the tumor growth curve were compared between
groups using an ANOVA test. Data were expressed as
Mean standard deviation. Graphs and statistics were
obtained using GraphPad Prism 5.0 (GrphPad Software,
Inc., California, USA) and STAT software (version 12.1,
StataCorp LP, College Station, Texas, USA). A P-value
< 0.05 was considered as significant.
RESULTS
Light Dose During Low-Dose PDT is Critical for
Selective Tumor Drug Uptake Enhancement
In a first set of experiments, we treated H-Meso1 tumors
grown in dorsal skinfold chambers by L-PDT using a
fluence of 5, 10, 30, and 50 J/cm2 (Fig. 1A). Animals
underwent epifluorescence intravital microscopy following
FITC-D injection. This allowed FITC-D distribution
assessment over a period of 45minutes. Typical images
of the intravital imaging of FITC-D over time are shown for
the different treatment groups (Fig. 1B). We observed that
30 and 50J/cm2 treatments caused clear occlusion of the
tumor vasculature while normal tissue demonstrated
enhanced drug uptake (Fig. 1A). FITC-D leakage in the
different tissue compartments (tumor/normal) were quan-
tified over time (Fig. 2A).We found that FITC-D leakage in
tumors was significantly enhanced in the 10 J/cm2 group
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Fig. 1. a), Nudemouse bearing a customdesigned dorsal skinfold chamber. This windowmodel has
the advantage to be very light compared to other systems available (2 g in weight) and to enable full
tumor observation because of the big window coverslip; b), intravital epifluorescent imaging of the
distribution of FITC-D in the tumor and normal tissue of H-Meso1 tumors grown in dorsal skinfold
chambers. Three sequences (a-c, d-f, g-h and h-j) per treatment group (fluence of 5, 10, 30, and 50J/
cm2) are represented for time points 5, 25, and 45minutes following FITC-D injection. FITC-D
leakage distributed in normal and tumor tissue after 5 J/cm2 but the accumulation of FITC-D in
tumors was increased with 10J/cm2. Higher L-PDT fluence (30 and 50J/cm2) caused a vascular
shutdown of the tumor vasculature while normal tissue leakage was enhanced.
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compared to the 5 J/cm2 group (Fig. 2A). Interestingly, the
FITC-D quantification in tumors in the 30 and 50J/cm2
groups showed enhanced uptake. However, a precise
analysis of the tumor vasculature showed clear tumor
vascular shutdown and the FITC-D intensity increase was
due to enhanced leakage of the FITC-D in normal tissue
located behind the observed tumor. Regarding normal
tissue FITC-D uptake, no change in normal tissue uptake
was observed between 5 and 10J/cm2 treatments while 30
and 50 J/cm2 treatments caused significant FITC-D distri-
bution enhancement. We then plotted tumor to normal
tissue FITC-D uptake ratio to assess the best light dose
range formaximal FITC-D uptake in tumors withminimal
change in normal tissue (Fig. 2C). We found that 10J/cm2
was the optimal L-PDT light dose for best distribution in
tumors with minimal normal tissue leakage.
Effect of Low-Dose PDT Combined With Systemic
Lipoplatin
W
Chemotherapy on Tumor Response
To determine if the enhanced distribution in chemother-
apy induced by L-PDT translated into a better tumor
response, we determined the growth of subcutaneous
tumors that express luciferase using calliper measure-
ments and whole body bioluminescence assay (Fig. 3A, B).
Luciferin was injected intra-peritoneally and, in viable
tumor cells that expressed luciferase, caused the creation
of light that could be quantified by bioluminescence. This
model allowed a precise quantification of the viable tumor
cells by whole body luminescence imaging. We treated
animals by L-PDT alone (10J /cm2), LipoplatinTM alone, L-
PDTþLipoplatinTM and no treatment. Tumor viability
was then assessed using the bioluminescence assay. We
found that L-PDT alone and LipoplatinTM alone caused a
Fig. 2. a), FITC-D fluorescence quantification in tumor and normal tissues over time (50minutes)
after low-dosePDTwith different irradiances (5 animals/group). FITC-Dfluorescence accumulation
in tumors was significantly enhanced with 10J/cm2 compared to 5 J/cm2 conditions. For higher
doses of irradiance (30 and 50J/cm2), FITC-D did not circulate in tumor vessels (that were clogged)
but fluorescence in the normal tissue was enhanced significantly. Overall, 10J/cm2 irradiance had
the best effect on tumor uptake of FITC-D with no effect in the normal tissue. b), Tumor to normal
FITC-D fluorescence plotted at 5 and 50minutes following FITC-D injection for different L-PDT
conditions or control (Visudyn with no light administration). L-PDT at a 10J/cm2 fluence caused a
significantly better tumor to normal tissue uptake of FITC-D than all other PDT conditions and
therefore appears to be the most favorable for FITC-D distribution in tumors while limiting normal
tissue uptake (*: P<0.05).
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slight decrease in tumor growth compared to controls
although not significant (Fig. 3A). However, combination
therapy caused a persistant and long lasting drop in tumor
growth that was significant and that lasted up to 28 days.
These findings were also found with calliper measure-
ments of the tumor volume that was significantly lower
over time in the combined treatment compared to control
(Fig. 3B).
DISCUSSION
In the current study, we evaluated the efficacy and
selectivity of Visudyne
1
-mediated low-dose PDT at
different fluences in an H-Meso1 heterotopic xenograft
model in nude mice. In this model, we found that a fluence
of 10 J/cm2 with a fluence rate of 100mW/cm2 were optimal
to enhance vascular transport of macromolecules in
tumors while leaving normal tissues unaffected. It was
previously shown that L-PDT could enhance the distribu-
tion of chemotherapeutics in various tumor models
including colon cancer, mesothelioma, adenocarcinoma,
prostate cancer and sarcoma [2,3,5,9–13]. Most of these
studies used different photosensitisers with fluence rates
ranging between 3 and 100mW/cm2 and fluences ranging
between 10 and 88J/cm2. The importance of fluence and
fluence rates were studied in a model of colon cancer [5]. It
was shown that vascular L-PDT enhanced tumor drug
distribution when fluence ranged between 48 and 88 J/cm2
with fluence rates ranging between 14 and 28mW/cm2 [5].
Interestingly, the study did not look at higher fluence rates
because of light exposure timing issues making these
Fig. 3. a) Bioluminescence assay quantification of the growth of H-Meso1-luc tumors over a period
of 28 days treated either by L-PDT 10J/cm2 alone, Lipoplatin
1
alone, L-PDT 10J/cm2þLipoplatin1
and untreated controls. Tumor growth curves showed a significant tumor growth delay after
combined treatment compared to controls (*: P<0.05 of control photoluminescence values
compared to combination treatment). b) Tumor growth curves of control, Lipoplatin
1
alone, L-PDT
10J/cm2alone and combined treatment are shown over time.Combined therapy shows significantly
lower sizes of tumors compared to the control tumors (*: P<0.05).
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conditions difficult to compare to what was reported.
Fluence and fluence rates are of major importance as they
affect the photodynamic reaction, creation of oxygen
species and oxygen depletion which are key for the
biological effects of PDT [8]. In addition, vascular modula-
tion by photodynamic therapy also involves the optimal
location of the photosensitizer in the perivascular area
(typically estimated at 15minutes after photosensitizer
injection for Visudyne
1
). In this study, we chose an
alternative approach to the previously published studies
and used a high fluence rate of 100mW/cm2 with low
fluencies ranging between 5 and 50 J/cm2. The major
rational for a high fluence rate was to have a rapid light
delivery and take maximal advantage of the short
perivascular location of Visudyne
1
for best vessel modula-
tion. In addition, based on previous data published by our
group and others, we chose a fluence range that covered
tumor and normal tissue vessel modulation. Our findings
are concordant with previously published data with the
advantage our light distribution was shorter. This
approach did not preclude vascular modulation by L-
PDT [5,8].
In our study, we found that L-PDT fluence variation had
different effects in normal and tumor tissues. For tumors,
our findings show there was an optimal fluence for
maximal vascular transport enhancement. Any variation
from the optimal fluence (lower or higher fluencies) caused
either no vascular enhancement or tumor vascular
shutdown. In normal tissue however, increasing fluencies
enhanced vascular transport in a somewhat linear fashion.
Previous observations have already suggested that the
mechanism for drug distribution enhancement by L-PDT
is different in normal and tumor tissues [4]. In normal
tissues, it was demonstrated that the fluencies required for
drug distribution enhancement are, on average, 10 fold
higher to the ones necessary in tumor tissues [9,10,13].
Also, although the precise mechanism for vascular
transport enhancement is not well known, it was demon-
strated that selectins and the immune system played an
important role for drug distribution enhancement in
normal tissue while this was not the case in tumor
tissues [9,10]. Here, wewere able to show that the different
effects of L-PDT between normal and tumor tissues can be
exploited: with a fluence of 10 J/cm2, we were able to
significantly enhance drug distribution in tumors while
leaving normal tissues unaffected. In addition, this study
shows the value of the differential L-PDT effect between
normal and tumor tissues which can be exploited to
selectively target cancer while avoiding excessive normal
tissue accumulation and toxicity.
A clinical translation of our study in patients, although
the procedure remains complex and invasive, could be of
interest in superficially spreading tumors such as meso-
thelioma or oligometastatic pleural disseminations. In-
deed, this therapy has limited side effects while enhancing
drug distribution in tumors significantly. However optimal
drug/light conditions aremandatory for tumor blood vessel
L-PDT to be successful. Therefore, a better understanding
of how photosensitization modifies the vascular function
and refinements of in situ L-PDT monitoring are manda-
tory for the translation of this concept in a clinical setting.
Few parameters currently exist to assess the impact of L-
PDT on the vasculature and thus determine the appropri-
ate sequence of administration of chemotherapy following
L-PDT for best therapeutic results. Based on our findings,
the choice of the fluence should be sufficiently high to
enhance drug distribution in tumors but low enough not to
affect normal tissue and causemorbidity. In addition to the
fluence and fluence rate monitoring, one approach could
consist in the assessment of interstitial fluid pressure and
laser Doppler blood flow in tumor and normal tissues
which were shown to well correlate with the drug
distribution enhancement effect of L-PDT [4].
In this study, we have observed, in real time, the
vascular transport changes of living tumors and surround-
ing normal tissue following L-PDT. Intravital microscopy
is a complex but robust methodology to visualize the result
of a therapy on the tumor and its environment [17–20]. The
time lapse experiments using the optimal 10 J/cm2 fluence
showed that L-PDT caused enhanced vascular transport in
tumors but not normal tissues. The macromolecular dye
FITC-Dwas chosen in this study as its size is comparable to
modern macromolecular cytostatic compounds (100nm).
Due to its fluorescent properties, we could document by
intravital fluorescence microscopy its intravascular distri-
bution after intravenous injection. FITC-D was injected
one hour after L-PDT as previous work has suggested that
vascular convection was enhanced during the first hour
following L-PDT [5]. We found that FITC-D kept accumu-
lating in tumor tissue but not normal tissue with the
optimal L-PDT light fluence and reached a plateau
approximately 45minutes after injection (1 h45 after L-
PDT treatment). These findings suggest that the vascular
changes in tumors induced by L-PDT are long-lasting and
suggest a change in the vascular structure rather than a
vasospasm. This is of interest as it could be exploited for
repeated chemotherapy administration regimens accord-
ing to the duration of the enhanced drug distribution
window induced by L-PDT. Previous work has shown that
a single PDT treatment could cause sequential vascular
changes that were durable over time [1,21] but further
studies are required to better define the vascular enhance-
ment window. Altogether, our data show the robustness of
our animal model for multiple timepoint vascular modula-
tion observations with each timepoint being compared to
the initial situation. From a statistical perspective, the
quality of our data was enhanced by this approach.
Finally, we determined tumor response following L-PDT
combined to Lipoplatin
1
. For this, we chose a macromolec-
ular liposomal form of cisplatin, a drug currently used for
the treatment of malignant pleural mesothelioma. The
liposomal formulation of cisplatin was developed to reduce
its systemic toxicity while simultaneously improving its
efficacy [22,23]. The ideal L-PDT treatment conditions
(10 J/cm2) were selected according to the first part of the
study in order to achieve selective tumor drug delivery.We
observed a strong and significant effect on tumor growth of
L- PDT combined to systemic chemotherapy, compared to
FLUENCE PLAYS A CRITICAL ROLE ON THE SUBSEQUENT DISTRIBUTION OF CHEMOTHERAPY 329
control animals (no treatment or L-PDT/Lipoplatin
1
alone). The combined L-PDTþLipoplatin1 group had a
long lasting tumor growth decrease with no clear evidence
of tumor regrowth at 28 days. When comparing this to the
L-PDT and Lipoplatin
1
monotherapy, the combined
treatment group seemed to be synergistic. Further work
is required to prove this element. However, this finding is
of major importance for the L-PDT concept validation in
the clinics.
We conclude that photodynamic drug delivery with the
appropriate fluence and fluence rate has the potential to
increase tumor uptake of systemically administrated
drugs in a tumor-specific fashion.
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Background: Low-dose, Visudyne1-mediated photody-
namic therapy (photo-induction) was shown to selectively
enhance tumor vessel transport causing increased uptake
of systemically administered chemotherapy in various
tumor types grown on rodent lungs. The present experi-
ments explore the efficacy of photo-induced vessel modu-
lation combined to intravenous (IV) liposomal cisplatin
(Lipoplatin1) on rodent lung tumors and the feasibility/
toxicity of this approach in porcine chest cavities.
Material and Methods: Three groups of Fischer rats
underwent orthotopic sarcoma (n¼ 14), mesothelioma
(n¼14), or adenocarcinoma (n¼12) implantation on the
left lung. Half of the animals of each group had photo-
induction (0.0625mg/kg Visudyne1, 10 J/cm2) followed by
IV administration of Lipoplatin1 (5mg/kg) and the other
half received Lipoplatin1 without photo-induction. Then,
two groups of minipigs underwent intrapleural thoraco-
scopic (VATS) photo-induction (0.0625mg/kg Visudyne1;
30 J/cm2 hilum; 10J/cm2 apex/diaphragm) with in situ
light dosimetry in combination with IV Lipoplatin1
administration (5mg/kg). Protocol I (n¼ 6) received Lip-
oplatin1 immediately after light delivery and Protocol II
(n¼9) 90minutes before light delivery. Three additional
animals received Lipoplatin1 and VATS pleural biopsies
but no photo-induction (controls). Lipoplatin1 concentra-
tions were analyzed in blood and tissues before and at
regular intervals after photo-induction using inductively
coupled plasma mass spectrometry.
Results: Photo-induction selectively increased Lipopla-
tin1 uptake in all orthotopic tumors. It significantly
increased the ratio of tumor to lung Lipoplatin1 concen-
tration in sarcoma (P¼ 0.0008) and adenocarcinoma
(P¼ 0.01) but not in mesothelioma, compared to IV drug
application alone. In minipigs, intrapleural photo-induc-
tion combined to systemic Lipoplatin1 was well tolerated
with no toxicity at 7 days for both treatment protocols. The
pleural Lipoplatin1 concentrations were not significantly
different at 10 and 30 J/cm2 locations but they were
significantly higher in protocol I compared to II (2.370.7
vs. 1.37 0.7ng/mg, P < 0.001).
Conclusion: Visudyne1-mediated photo-induction selec-
tively enhances the uptake of IV administered Lipoplatin1
in rodent lung tumors. Intrapleural VATS photo-induction
with identical treatment conditions combined to IV Lip-
oplatin chemotherapy is feasible and well tolerated in a
porcine model. Lasers Surg. Med.
 2015 Wiley Periodicals, Inc.
Key words: adenocarcinoma; mesothelioma; sarcoma;
rodent; minipig; lung; lipoplatin; chemotherapy; photo-
dynamic therapy; visudyne
INTRODUCTION
Malignant pleural disease is a frequently observed
clinical entity that has an important social, medical, and
economic burden [1]. Current treatment is based on
systemic cisplatin-based chemotherapy but success is
limited due, in part, to the poor penetration of cytostatic
agents into tumors. Recently, several studies have shown
Conflict of Interest Disclosures: All authors have completed
and submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest and none were reported.
Xingyu Wang, Fabrizio Gronchi, Solange Peters, and Jean
Yannis Perentes contributed to this work equally.
Contract grant sponsor: Swiss National Foundation; Contract
grant numbers: 3200030, 135197.
Correspondance to: Hans-Beat Ris, MD, Service de chirurgie
thoracique, CHUV, rue du Bugnon 21, 1011 Lausanne. E-mail:
hans-beat.ris@chuv.ch
Accepted 13 September 2015
Published online in Wiley Online Library
(wileyonlinelibrary.com).
DOI 10.1002/lsm.22422
 2015 Wiley Periodicals, Inc.
that vessel targeted photodynamic therapy (PDT) at low
drug-light conditions could selectively enhance the uptake
and distribution of subsequent systemically administered
macromolecular cytostatics in tumors. Interestingly, this
pre-treatment step had no effect on the surrounding
normal tissue which suggested vessel targeted low-dose
PDThad a tumor specific effect (photo-induction) [2–6].We
and others have shown that Visudyne1-mediated photo-
induction selectively increased the uptake of liposomal
cytostatics to pleural tumors grown orthotopically in
rodents[3–5] and delayed tumor growth of human meso-
thelioma xenografts compared to chemotherapy alone [6].
It is therefore, suggested that intrapleural photo-induction
may enhance theuptake of subsequently applied cytostatics
such as macromolecular cisplatin to selectively enter
pleural tumors and thereby improve treatment outcome.
Recently, liposomal cisplatin (Lipoplatin1) has been
formulated and tested thoroughly in preclinical and phase
I, II, and III trials for various malignancies. It is expected
to be applied in pleural malignancies in the near
future [7–9]. Therefore, in the present preclinical study,
we investigate the effect of intrapleural Visudyne1-
mediated photo-induction combined to systemic Lipopla-
tin1 chemotherapy on various subpleural tumor types
grown orthotopically on rodent lungs (proof of concept) and
then assess the feasibility and toxicity of this approach
applied by video-assisted thoracoscopic surgery (VATS) in
the pleural cavities of minipigs.
MATERIALS AND METHODS
Photo-Induction and Systemic LipoplatinW
Chemotherapy on Tumors Grown
Study design. Three groups of Fischer rats underwent
orthotopic subpleural generation of sarcoma (n¼14),
mesothelioma (n¼14), or adenocarcinoma (n¼ 12) in the
lower lobe of the left lung. When the tumors had reached a
size of 4–6mm in diameter, half of the animals of each
group underwent low-dose Visudyne1-mediated photody-
namic therapy (photo-induction) of the tumor and the
surrounding lower lobe followed immediately after light
delivery by intravenous (IV) injection of Lipoplatin1 that
was allowed to circulate for 60minutes. At this time point,
the treated tumor and surrounding lung were harvested
and processed for Lipoplatin1 tissue concentration meas-
urements. The other half of the animals of each group
underwent Lipoplatin1 administration without photo-
induction (controls).
Animals and housing. Forty male Fischer rats
(Charles River, France) weighting 250–300 g were used
and treated in accordance with the National Institute of
Health Guidelines for the Care and Use of Laboratory
Animals and the Local Ethical Committee of the Universi-
ty of Lausanne.
Tumor cell lines. Syngeneic mesothelioma II-45 and
methylcholanthrene-induced sarcoma cell lines were
cultivated at 378C with 5% CO2 in 20ml of RPMI-1,640
medium containing glutaril, 10% fetal bovine serum (FBS),
and 1% penicillin/streptomycin (Invitrogen Corporation,
GIBCOTM Life Technologies Ltd, Paisley, UK). A synge-
neic adenocarcinoma cell line (13,762 MAT B III) was
cultivated at 378C with 5% CO2 in 20ml of McCoy’s 5a
medium containing 1.5ml L-Glutamin and 2.2 g/L sodium
bicarbonate, 10%FBS (InvitrogenCorporation,GIBCOTM
Life Technologies Ltd, Paisley, UK). Tumor cell viability
was assessed in a hemo-cytometer after centrifugation at
1,000 g for 4minutes, washing, re-suspension in PBS and
addition of trypan blue. The cell suspension was adjusted
to a density of 5 107 vital cells/ml for subpleural
injection [4].
Anesthesia. Animals were anesthetized by intraperito-
neal injection of pentobarbital sodium (50mg/kg) followed
by oro-tracheal intubation and ventilation with a standard
rodent ventilator (Model 683, Harvard Apparatus, Les
Ulis, France) with a mixture of oxygen and isofluran (0.5–
2%), a tidal volume of 10ml/kg with a positive end
expiratory pressure (PEEP) of 2–3 cmH2O, and a respira-
tory rate of 75–90/minutes. Postoperative analgesia
consised of subcutaneous administration of 0.05mg/kg
Buphrenorfine1 before extubation and then twice a day for
3 days after surgery.
Subpleural tumor generation in the left lower
lung lobe. The animals were anesthetized and a left-sided
mini-thoracotomy (7th intercostal space) was performed
with subpleural injection of 0.1ml tumor cell solution into
the left lower lobe followed by closure of the thoracotomy
and extubation [3].
Intraoperative photo-induction of the tumor-
bearing lungs. After anesthesia a left-sided thoracotomy
was performed through the 4th intercostal space with
division of the inferior pulmonary ligament and mobiliza-
tion of the left lung containing the subpleural tumor. The
left external jugular vein was cannulated and 0.0625mg/
kg Visudyne1 (Novartis, Hettlingen, Switzerland), dis-
solved in NaCl 0.9% and glucose 5% was injected. After a
drug/light interval of 15minutes, 689nm laser light
(35mW/cm2, 10 J/cm2) was delivered to the tumor and
the lower lobe through an optical microlens fiber (Model
FD; Medlight, Ecublens, Switzerland) with the incident
laser beam centered on the tumor and a treatment spot of
30mm diameter (treatment time 5minutes). In previous
studies using an identical set up and drug-light conditions,
no thermal effect has been measured at the surface of the
treated area [3]. The fluence rate and the fluence were
measured in real-time by a previously described light
dosimetry system [10,11]. During and after PDT, ventila-
tion with a positive end expiratory pressure (PEEP) of 2–
3 cmH2O was maintained.
Intravenous administration of LipoplatinW. Imme-
diately after laser light delivery, 5mg/kg Lipoplatin1 was
injected intravenously via the jugular vein. The circulation
time of Lipoplatin1 was 60minutes with the lung
ventilated with a PEEP of 2–3 cm H2O.
Assessment of LipoplatinW concentrations in tu-
mor and lung tissues. After 60minutes of Lipoplatin1
circulation time, the tumor and normal tissue of the left
lung were analyzed separately by use of Inductively
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Coupled Plasma Mass Spectrometry (ICP-MS) as de-
scribed below. After dissection and excision of the tumor,
the lung was cut in three pieces corresponding to the
upper, middle and lower part of the lung. The coefficient of
variation (CV%) and the ratio between tumor and lower
lobe Lipoplatin1 concentration were determined for each
animal [3].
Photo-induction Combined to Systemic LipoplatinW
Chemotherapy in Porcine Chest Cavities
Study design. Fifteen animals received IV Lipoplatin1
chemotherapy at a dose of 5mg/kg combined toVisudyne1-
mediated intrapleural low-dose photodynamic therapy via
video-assisted thoracic surgery (VATS) with the following
treatment conditions: 0.0625mg/kg Visudyne1 IV; drug-
light interval 15minutes; light dose of 10 J/cm2 at the apex
and diaphragm and 30 J/cm2 at the dorsal and ventral
hilum. These drug-light conditions were chosen based on
our previous studies with the 10 J/cm2 being the optimal
fluence for tumor but not normal vessel permeabilisation
and the 30 J/cm2 being the first fluence with a potential
leakage effect on normal vessels [6]. Six animals received
Lipoplatin1 immediately after light delivery (Protocol I)
and nine animals 90minutes before light delivery (Protocol
II). Three animals in group II were treated at identical
treatment conditions but with two lasers. Three animals
received Lipoplatin1 and underwent VATS pleural biop-
sies but without photo-induction (controls).
Pleural biopsies for Lipoplatin1 concentration measure-
ments were harvested at 10 and 30J/cm2 regions before
and at regular intervals up to 90minutes after light
delivery. The postoperative course of all animals was
monitored for 7 days after surgery. At that time point,
autopsy was performed with histology and Lipoplatin1
concentration measurements performed in both chest
cavities and various organs.
Animals and housing. G€ottingen minipigs (Bern,
Switzerland) weighting 20–25kg were used and treated
in accordance with the National Institute of Health
“Guidelines for the Care and Use of Laboratory Animals”
and the Local Ethical Committee of the University of
Lausanne.
Intrapleural VATS photo-induction. Following in-
tramuscular sedation with ketamine 5mg/kg, xylasine
0.1mg/kg and atropine 0.1mg/kg, general anesthesia was
induced with isoflurane 2% using an FiO2 of 100%.
Anesthesia was maintained with isoflurane at a minimal
alveolar concentration of 1,5 supplemented with IV
meloxicam 0,4mg/kg and a transcutaneous fentanyl patch
50mcg/h. Endotracheal intubation, using a 7.0Malinkrodt
tube (Mallinkrodt Medical, Athlone, Ireland) was per-
formed after a 2.5mg/kg IV bolus of propofol. A 5ml
endobronchial blocker (Cook Medical, Bjaevereskov,
Denmark) was placed in the left main bronchus, using
an ultra slim single-use videoscope (Ambu1 aScopeTM 3
Slim, Ballerup, Denmark), for lung separation and single
lung ventilation (Datex Engstrom, Bromma, Sweden).
Immediately after lung isolation the FiO2 was reduced to
50% using an air/oxygen mixture, and the right lung was
ventilated with a tidal volume of 6ml/kg, a positive end
expiratory pressure of 5 cm H2O and a respiratory rate
adjusted to keep expired CO2 within normal limits (35–
40mmHg). A central venous line was inserted in the right
jugular vein for Visudyne1 and Lipoplatin1 administra-
tion and for blood sampling. Rectal temperatures were
measured continuously during the procedure and main-
tained at 37–388C with a heating blanket. Arterial
oxygen saturation, expired gases (O2, CO2, isoflurane)
and temperature were monitored continuously.
After general anaesthesia and exclusion of the lung, a
left-side video-assisted thoracoscopic surgery (VATS)
approach was performed with two thoracoports at the
6th and 7th intercostal space, respectively. Four 0.8mm
diameter isotopic probes (Model IP; Medlight, Ecublens,
Switzerland) were inserted for real-time in situ light
dosimetry and placed under endoscopic vision at different
locations of the cavity (ventral hilar/dorsal hilar/apical/
diaphragmatic). A dose of 0.0625mg/kg Visudyne1 was
then IV administrated. After a drug-light interval of
15minutes, illumination of the chest cavitywith laser light
at 689nm and non-thermal fluence rates (typical average
value of 35mW/cm2) was performed by use of one or two
spherical light distributors (Model SD; Medlight, Ecu-
blens, Switzerland) coupled to one or two diode lasers,
respectively. The light distributor was inserted into one or
two a sterile, commercially available intubation tubes
filled with saline solution which were brought into the
chest cavity though aexisting thoracoports. These light
distributors were connected to laser diodes emitting at
690nm (Ceralas PDT, 690/4–5W/3nm/400mm, Ceram-
Optec GmbH, Bonn, Germany). Light delivery was guided
by in situ light dosimetry and on-line measurements of the
fluence and fluence rate at each of the four localisations
within the chest cavity until each of the four probes had
recorded a cumulated fluence of 10 J/cm2 (apical/diaphrag-
matic) and 30 J/cm2 (ventral hilar/dorsal hilar), respec-
tively [10,11]. This setup designed to measure in vivo the
fluence and fluence rate simultaneously and at several
locations is based on the integration of a commercially
available multichannel (up to 12 channels) power meter
(model OP710 SI; OptoTest Corp. Camarillo, CA) equipped
with isotropic detectors (Model IP; Medlight SA, Ecublens,
Switzerland) with a standard laptop. This system was
customized in the sense that the silicon photodiodes
integrated in the setup were replaced with diodes with
an optimized spectral sensitivity for the detection of light
690nm. A homemade program written in Cþþ/cli (Stud-
zinski Medias & Electronique, Lausanne, Switzerland)
was developed to operate this power meter, and to process
and display the data.
Blood samples and pleural biopsies were harvested for
Lipoplatin1 concentration measurements in the 10 J/cm2
and 30 J/cm2 regions before and at 10minutes intervals up
to 90minutes after light delivery. At that time point, the
thoracoports were removed, a chest tube was inserted and
extubation was performed. At the end of the procedure, the
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insertions were closed in layers after introduction of a
chest tube (16 gauge). Extubationwas performed following
ventilation with room air with continued PEEP and the
chest tube was removed. Before waking up the animals, IV
paracetamol (15mg/kg) and meloxicam (0.4mg/kg) were
administered for postoperative analgesia.
Systemic LipoplatinW administration. Lipoplatin1
was administered IV at a dose of 5mg/kg as perfusion over
5minutes in anesthetized animals through the cannulated
jugular vein. In protocol I, it was administered immedi-
ately after light delivery, in protocol II 90minutes before
light delivery. The two treatment protocols were chosen to
examine whether different Lipoplatin1 circulation times
may influence the photo-induced permeabilisation effect
on normal organs.
Assessment of lipoplatinW concentrations in blood
and tissue samples. Blood samples (2ml) and pleural
biopsies of 10 and 30 J/cm2 regions were harvested for
Lipoplatin1 concentration measurements before and at
10minutes intervals up to 90min after light delivery by
use of inductively coupled mass spectrometry (IC-MS). All
samples were stored at 808C.
Follow-up. After extubation, the animals were ob-
served for 7 days at the farm under supervision of
a veterinary. Eating behavior, breathing frequency,
wound healing, and treatment-related side effects were
recorded.
Assessment of treatment-related toxicity. At day
seven following surgery, autopsy was performed with
histological assessment and Lipoplatin1 concentration
measurements of various organs. After euthanasia with
pentobarbital 100mg/kg, a sterno-laparotomy was per-
formed and both chest cavities were inspected. Biopsies of
the pleura, lung diaphragm, aorta, heart, liver, kidney,
and skin were performed and processed for histological/
ICP-MS analysis. Histological examination of the slices
stained with haematoxylin and eosin (H&E) was per-
formed by a blinded pathologist.
Assessment of LipoplatinW Concentrations by
Inductively Coupled Plasma Mass Spectrometry
The weight of tissue aliquot to be assayed for platinum
was comprised between 50 and 300mg. A volume of
500mL of nitric acid 5M was added to tissue aliquot, and
the obtained suspension was heated at 608C overnight in
a water bath. After ca 16hours of mineralisation, the
resulting yellow suspension containing solid tissue
residues was sonificated for 30 seconds. A volume of
4.8mL of nitric acid 2% was then added, and the
resulting tissular suspension was subjected to a second
sonification for 30 seconds. The homogeneous tissue
suspension was finally centrifuged at 2,000g for 10mi-
nutes. A 5mL-volume of clear pale yellow supernatant
was available for the assay of platinum by Inductively
Coupled Plasma Mass Spectrometry (ICP-MS). A double
focusing reverse geometry mass spectrometer was used
(FinniganTM Element2 High Performance High Resolu-
tion ICP-MS instrument). The mass resolution was set
to 500 in order to take advantage of the high signal
transmission used in the low-resolution mode to increase
the analytical sensitivity of Pt isotopes. The Element2
instrument was used with a standard glass spray
chamber and Meinhard nebulizer. Calibration standards
were prepared through successive dilutions using blank
tissues solution, of 1mg l1 ICPMS stock solution
(Bernd Kraft). Suprapur1 grade nitric acid (65% Merck)
was used for the preparation of standards (2þ1000) and
the dilution of samples. Ultrapure water was produced
using Milli-Q1 Ultrapure Water System (Millipore,
Bedford). Rh was used as Internal Standard for samples
and standards to correct signal drift. 100ml of 100mg l1
Rh stock solution were added to 10ml of standards and
samples.
Statistical Analysis
Photo-induction on rodent lung tumors. Lipopla-
tin1 concentrations in tumors and normal lung parenchy-
ma of rodents and in blood and tissue samples of minipigs
were compared using a two-tailed Student t-test for
unrelated samples. The sameholds true for the comparison
of the ratio between tumor and normal lung drug uptake.
The coefficient of variation in Lipoplatin1 lung tissue
levels was determined using the drug concentration in the
three locations of treated lungs and compared using
the Student’s t-test. A bidirectional hypothesis was applied
and significance was considered with P< 0.05.
Intrapleural photo-induction on minipigs. Lip-
oplatin1 concentrations in blood and tissue samples with
and without photo-induction were compared using the
Student t-test for unrelated samples. A bidirectional
hypothesis was applied and significance was considered
with P<0.05.
RESULTS
Photo- Induction Combined to Systemic
LipoplatinW Chemotherapy on Lung Tumors
Lipoplatin concentrations in tumors and normal
lung tissues. Table 1 shows the Lipoplatin1 concen-
trations in adenocarcinoma, sarcoma and mesothelioma
tumors as well as in the surrounding normal lung tissue,
with and without PDT pre-treatment. Photo-induction
enhanced Lipoplatin1 uptake in all three tumor types and
significantly increased the ratio between tumor and lung
drug concentrations in sarcoma (P¼ 0.0008) and adeno-
carcinoma (P¼ 0.01) but not mesothelioma, compared to
IV drug administration alone. The coefficient of variation
(CV%) of Lipoplatin1 concentrations in the three parts of
the lungs did not differ significantly between treatment
groups indicating a homogeneous Lipoplatin1 distribu-
tion in the lungs for all treatment groups, including those
with photo-induction.
Intrapleural Vats Photo-induction Combined to
Systemic LipoplatinW in Porcine Chest Cavities
Light delivery. The analysis of the on-line measured
and computer-stored fluences during light delivery
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revealed a homogeneous illumination of the chest cavity
with appropriate cumulated fluences at the different
locations for both modes of illumination (one vs. two
lasers, Fig. 1a). The mean time to obtain 10J on the apex/
diaphragm and 30J in the hilar region were homogenous
and reported in Fig. 1b. The mean illumination time to
obtain the required light dose at different locations was
shorter when using two lasers compared to one (27.6 19
vs. 8.51minutes to obtain 10J/cm2 to the chest cavity
using one or two lasers, respectively, Fig. 1c).
TABLE1. LipoplatinConcentration inTumorsandLowerLobeofRodentLungs (meanSD)After IVLipoplatinW
Administration (5mg/kg), With and Without VisudyneW-Mediated Photo-Induction (10J/cm2)
n Tumor (ng/mg) Lower Lobe (ng/mg) Ratioa CV (%)b P valuec
Sarcoma
Lipoplatin1 þ PDT 7 2.7  0.8 3.3  1.0 0.8  0.1 34.2 0.0008
Lipoplatin1 7 2.3  1.4 3.9  2.1 0.6  0.1 54.6
Adenocarcinoma
Lipoplatin1 þ PDT 7 3.2  0.8 2.3  0.5 1.4  0.4 32.6 0.016
Lipoplatin1 7 2.4  0.3 2.7  0.5 0.9  0.1 23.2
Mesothelioma
Lipoplatin1þ PDT 6 2.9  0.9 3.2  1.2 0.9  0.2 33.2 0.5
Lipoplatin1 6 2.3  0.6 2.6  0.4 0.9  0.1 24.3
aRatio of Lipoplatin1 concentration between tumor and normal surrounding lung tissue (median/range).
bCoefficient of variation of Lipoplatin1 uptake in three different parts of the treated lung.
cP values between ratios of tumor to normal lung Lipoplatin1 concentrations, with and without photo-induction.
Fig. 1. Laser light delivery in the chest cavities of minipigs during photo-induction: (a), real-time
measurement of the cumulative fluence applied to the four locations of the chest cavity in one of the
animals from our experiment; (b), time interval (minutes, meanSD) of illumination in order to
reach the defined cumulative fluence at different locations in the chest cavities during photo-
induction (10 J/cm2 to apex and the diaphragm, 30J/cm2 to the ventral and dorsal hilum,n¼12); (c),
time interval (minutes, meanSD) of illumination to reach the required cumulative fluence within
the chest cavities using one (n¼12) or two lasers (n¼3).
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LipoplatinW concentration measurements in
blood and tissue. For both treatment protocols, the
Lipoplatin1 concentrations were assessed in blood and in
pleural biopsies in the 10J and 30J/cm2 treated regions
before andat 10minutes intervals up to 90minutes following
photo-induction. Also, Lipoplatin concentrations in blood
and in various organs of the operated andnon-operated sides
were assessed 7 days after surgery. In protocol I, the
Lipoplatin1 concentrations in pleural biopsies reached a
plateau value 10minutes after light delivery without
significant differences between the 10J and 30J/cm2
locations and between animals with and without photo-
induction (Fig. 2a). The assessment of blood Lipoplatin1
concentration revealed a similar kinetic to that observed in
tissues (Fig. 2b). The pleura Lipoplatin1 concentrations
assessed 10minutes after light delivery were significantly
higher for treatment protocol I compared to II (2.37 0.7ng/
mg vs. 1.37 0.7ng/mg, P¼ 0.001, Fig. 3a). The same holds
true for blood Lipoplatin1 concentrations (25.2213ng/ml
vs. 7.04 2.2ng/ml,P¼ 0.003,Fig. 3b).At day7,Lipoplatin1
concentrations were not significantly different between
animals pre-treated or not by photoinduction except for
lung tissues on the operated side: Control animals had a
higher Lipoplatin1 lung uptake compared to the contro-
lateral lung (controls) and to animals treated by photo-
induction (P< 0.05, Fig. 4).
Toxicity and feasibility. The procedure was well
tolerated in all animals without relevant side effects,
intrapleural or chest wall infections, or toxicity. All
animals showed a normal eating behavior and stable
weight up to 7 days following surgery with no skin
phototoxicity which was specifically assessed at the site
of surgery and the site of pulse oxymetry measurement
(left ear) during and 7 days after the procedure.
Tissue injury.Anautopsywas performed in all animals
7 days after the intervention. Macroscopic and histological
analysis revealed no abnormality or injury apart from
discrete and localized pleural adhesions within the
operated chest cavity. Histological assessment did not
reveal injuries of intrathoracic organs; there were no
differences in histology of lung, pleura, diaphragm, heart,
and great vessels between the operated vs contralateral
chest cavities or between animals with and without photo-
induction (Fig. 5). The same holds true for histological
analyses of liver, kidney and skin. Also, the use of one
versus two lasers had no effect on the macroscopic and
histological assessment of intrathoracic organs.
DISCUSSION
Photodynamic therapy (PDT) has emerged as an
attractive cytotoxic treatment modality for superficially
growing tumors [12]. It was tested in the clinics for a
variety of malignancies including malignant pleural
diseases [13–20] but had important side effects and toxicity
when large surfaces were treated [14,21]. The dominant
mechanism of action of conventional PDT is the local
generation of singlet oxygen, which results in the destruc-
tion of tumor cells and of tumor microvasculature [12].
However, it has been shown with lower drug light
conditions that PDT could cause a variety of vascular
effects ranging from a transient vasospasm to vessel
transport enhancement and vessel wall disintegration
with thrombosis [22–26]. Scientific interest, so far, was
mainly focused on the vessel-occlusive effects of PDTwhile
its vessel transport enhancement properties have only
recently been explored to improve the uptake and efficacy
of systemically administered cytostatics to tumors. In
contrast to conventional PDT which aims to obtain tumor
ablation by a shutdown of tumor vasculature or a cytotoxic
effect on tumor cells, this new PDT application requires
specific vessel-targeted photosensitizers, a short drug-
light interval to keep the sensitizer intravascular and
lower drug/light conditions than generally used for
standard PDT treatments. Recently, several studies
have explored low-dose PDT to enhance the transfer of
macromolecular cytostatic agents across the endothelial
barrier into the tumor interstitium [2–6]. These studies
have shown that PDT pre-treatment at low drug-light
conditions and using vessel targeted sensitizers such as
Visudyne1 could enhance the uptake and distribution of
systemically administered macromolecular cytostatics in
tumors while sparing the normal surrounding tissues (a
phenomenon called photo-induction). By facilitating the
tumor uptake of systemically administered chemotherapy,
photo-induction may contribute to control malignant
pleural deposits while avoiding the adverse effects of
conventional PDT on surrounding structures.
Fig. 2. Lipoplatin1 concentrations (a), in pleural biopsies at 10J and 30J/cm2 locations, and (b), in
blood before and at different time intervals following light delivery (meanSD) using protocol I
(Lipoplatin1 injection immediately after light delivery, n¼6). Controls animals (n¼3) received
VATS and Lipoplatin1 but no photo-induction.
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In previous experiments, we have shown that Visu-
dyne1-mediated photo-induction resulted in a significant
increase of liposomal doxorubicin uptake in mesothelioma,
adenocarcinoma, and sarcoma tumors on rodent lungs but
that the extent of tumor drug uptake paralleled tumor
vessel density [4]. Regarding drug-light conditions, Visu-
dyne1 was used as sensitizer and administered at half of
the dose recommended in patients (0.0625mg/kg) [27], a
short drug-light interval (15minutes) to keep the sensitiz-
er intravascular and a low fluence (10 J/cm2). This fluence
value was based on a previous studies performed in H-
Meso1 tumors grown in dorsal skinfold chambers [6]. In
this model, we found that a fluence of 10 J/cm2 was optimal
to enhance vascular transport of macromolecules in
tumors while leaving normal tissues unaffected; a higher
light dose, however, resulted in tumor vessel occlusion
which impeded tumor drug transfer [6]. Using these
optimized drug-light conditions for the treatment of
mesothelioma xenografts in nude mice, we determined
tumor response following Visudyne1-mediated photo-
induction combined to Lipoplatin1, a macromolecular
liposomal formulation of cisplatin, currently used in
clinical phase II and III trials [7–9]. We observed a
significant tumor growth delay after photo-induction
combined to systemic chemotherapy compared to
Lipoplatin1 chemotherapy alone, without evidence of
tumor re-growth up to 28 days after treatment [6].
Theprecisemechanismonhowphoto-inductionenhances
effective permeability of tumor vessels for macromolecular
cytostatics is still unknown. Interestingly, effective perme-
ability of tumorvessels and subsequent drugdistributiondo
not necessarily correspond to the intrinsic vessel perme-
ability. For example, it was well demonstrated that solid
tumors have wide networks of neovessels which are
permeable and cause interstitial fluid pressure (IFP) to be
high [28]. Macromolecular therapeutics are known to
depend on vascular convection for their extravasation
between the intra- and extra-vascular spaces [28] which
rely on tumor hydrostatic and oncotic pressures. The
increased IFP associated with the high vascular permeabil-
ity of tumor neovessels hinders convection and drug
delivery [28]. We have recently shown on rodent lung
tumors that photo-induction could cause a transient drop in
tumor but not normal tissue IFPwhile keeping tumor blood
flow constant whichmay explain enhanced drug convection
from the intravasal space into tumors and a subsequent
increase in tumor drug uptake [5].
This preclinical study was undertaken to assess intra-
pleural Visudyne1-mediated photo-induction combined to
liposomal cisplatin (Lipoplatin1) as a pathway to increase
the uptake and distribution of approved, cisplatin-based
chemotherapy in pleural tumors and thereby improve
outcome. This is potentially an attractive treatment
concept for superficially spreading chemo-resistant pleural
malignancies and may be considered in patients referred
for the thoracoscopic treatment of malignant pleural
effusion. It has a significant therapeutic potential for a
frequently encountered situation for which at present
there in no efficient therapy available. Our results indicate
that photo-induction selectively increased the tumor
uptake of subsequently IV administered Lipoplatin1 on
sarcoma, adenocarcinoma, and mesothelioma grown sub-
pleurally on rodent lungs. These results corroborate with
previous findings using the same model and photo-
induction conditions but liposomal doxorubicin: Sarcoma
and adenocarcinoma revealed a better tumor drug uptake
than mesothelioma which may be explained by a lower
tumor vessel density for this tumor type [4].
Fig. 3. Lipoplatin1 concentrations (meanSD) in (a), pleural biopsies and (b), blood 10minutes
after light delivery for treatment protocol I (Lipoplatin1 injection immediately after light delivery,
n¼6) and protocol II (Lipoplatin1 injection 90minutes before light delivery, n¼9), respectively (:
P<0.05 between Lipoplatin concentrations in the pleura and blood between protocols I and II).
Fig. 4. Lipoplatin1 concentrations (meanSD) in different
organs 7 days after photo-induction (P, pleura; L, lung; D,
diaphragm; H, heart; L, liver; K, kidney; S, skin; O, operated
chest; C, contralateral; non operated chest) in controls (n¼3) and
animals with photo-induction (n¼15).
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In the second part of our experiments and with identical
treatment parameters, we investigated intrapleural photo-
inductioncombined tosystemicadministrationofLipoplatin1
in tumor free minipigs as a safety and feasibility assessment.
Forthispurpose,weusedaCEcertifiedandcustomizeddevice
for clinical applications under sterile conditions which has
beendeveloped for intrapleural PDTandassessed inprevious
experiments in rodent and porcine chest cavities [10,11]. It
consists of a diode laser emitting a sensitizer-specific
wavelength coupled to an optical fiber-based light distributor
for endoscopic treatment, customised for applications in
operation theatres. Four isotropic optical fibres coupled to a
multichannel powermeter allowed for in situ, real-time
monitoring of fluence rates and fluences at different locations
within the chest cavity during illumination. This set up was
installed through a classical video-assisted thoracoscopic
setup used for conventional pleural biopsy or talcage in
patients. It allowed the homogenous delivery of controlled
light doseswithin the complex geometry of the chest cavity. A
similar set-up is currently used for patients undergoing
surgery and conventional intraoperative PDT for
mesothelioma [19,20].
The results of intrapleural photo-induction of porcine
chest cavities combined to IV Lipoplatin chemotherapy
indicate that this treatment is feasible and well tolerated.
With two lasers, the mean illumination time to deliver a
cumulative fluence of 10J/cm2 to the entire chest cavitywas
only of approximately 8.5minutes. We observed no periop-
erative or postoperative complications including skin
phototoxicity up to 7 days after the proceedure. This was
confirmedbyhistological examination ofmost organs 7 days
after treatment. The Lipoplatin1 concentration in pleura
biopsies reached a plateau approximately 10minutes after
drug administration and was significantly higher with
protocol I compared to protocol II. Thismay be explained by
the pharmacokinetic profile of Lipoplatin1 and its redistri-
bution pattern over time following IV injection. It does not
seem to be related to a photo-induction effect. However,
for both treatment schemes, there were no differences in
drug tissue concentrations between the 10J and 30J/cm2
locations suggesting that the combination of different
Lipoplatin1 circulation times and fluences did not lead to
normal vessel leakage and subsequent accumulation of
cyototoxic drugs at inappropriate sites.
Fig. 5. Histological assessment of intrathoracic organs at day 7 after operation: (a), heart; (b), lung;
and (c), diaphragmafter Lipoplatin1 administration and photo-induction (2 lasers)without evident
histological lesions except for discrete fibrinous reaction on the pleural surface; (d), heart; (e), lung;
and (f), diaphragm of a control animal without evident histological lesions except for discrete
fibrinous reaction on the pleural surface (H&E100).
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Our study has several limitations. First, the tumormodel
used did not rely on a pleural growing tumor but rather on a
syngeneic subpleural tumor model. This specificity of our
model could affect blood supply and chemotherapeutic drug
delivery which could affect our results. Thus, caution is
required in the interpretation of our results. However, our
model does allow uniform tumor growth with comparable
tumor sizes andvolumeswhich facilitates the comparison of
the Lipoplatin1 uptake following a standardized photo-
induction regimen. Second, the use of single lung ventila-
tion during photo-induction may alter the blood flow, local
tissue oxygenation, and interfere with drug uptake. Lung
collapse causes local hypoxia which has a vasospastic effect
on the pulmonary vasculature [30]. The latter has been
previously shown to cause heterogeneity in lung perfu-
sion [31]. In addition, oxygen levels and vascular perfusion
are important factors that can influence the photodynamic
therapy effect on vessels [2]. In our study, we observed an
increase in Lipoplatin1 uptake in the non-ventilated lung
on the operated side compared to the controlateral lung, but
only in control animals. Interestingly, Lipoplatin1 uptake
in the operated lung was decreased following photo-
induction compared to controls. The interpretation of this
data is difficult given the small number of animals of our
control group.However, asLipoplatin1 blood concentration
had reached a steady state in blood (injected before lung
exclusion), it could be that hypoxemic vasoconstriction
improved tissue drug uptake though an enhancement of
diffusion. On the other hand, photo-induction, which also
leads to microvascular alterations in the lung, might
interfere with these potential mechanisms and explain
the difference between drug uptake in control vs photoin-
duced lungs. Third, we have not formerly excluded a
hyperthermic effect on the pleural cavity in our porcine
model (no temperature measurement on the chest per-
formed during photoinduction). However, the light fluence
and fluence rates used in our study are several orders of
magnitude lower to those recommended for Visudyne1-
mediated PDT in the field of ophthalmology where the
avoidance of a hyperthermic effect is mandatory. Also the
animal temperature monitoring was mostly on the hypo-
thermic side with the requirement of a heating blanket
during the procedure which excludes an important hyper-
thermic effect. Forth, the laser light penetration has not
been fully assessed in our models. We found that 4mm
tumors in the rat could respond to photoinduction with
enhanced Lipoplatin uptake. We have also found in
previous studies that transcutaneous application of laser
lead to better Lipoplatin uptake and tumor response in
5mm mesothelioma tumors grown subcutaneously in
mice [6]. Also, based on the literature, our light conditions
should allow a penetration of at least 5mmwhich should be
sufficient to treat thin tumor deposits that are generally
observed in malignant pleural effusion in the clinics [29].
In conclusion, our experiments suggest that: i) Visu-
dyne1-mediated photo-induction with 10 J/cm2 selectively
increases the uptake of systemic liposomal cisplatin
(Lipoplatin1) in various pleural tumors grown orthotopi-
cally on rodent lungs (proof of concept); and ii) intrapleural
video-assisted thoracoscopic (VATS) photo-induction of
chest cavities combined to systemic Lipoplatin1 chemo-
therapy is feasible and well tolerated in minipigs, with
homogenous delivery of 10 J/cm2 using a customised
equipment for applications under sterile conditions in
the operation room. Based on these encouraging findings,
we plan to perform a clinical phase I trial that will explore
VATS intrapleural photo-induction as a mean to improve
the uptake and distribution of Lipoplatin1 in selected
patients with pleural malignancies.
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